The drug discovery collaboration will utilize Numerate’s in silico drug design technology to generate drug leads for an undisclosed cardiovascular disease target.
The platform will feature a set of proprietary algorithms that provide predictive models for molecular properties with accuracies comparable to laboratory testing.
The algorithms will allow the scientists to search and identify those with the highest probability of activity against a specific target.
Numerate chief executive officer Guido Lanza said the collaboration is focused on increasing the speed, cost-efficiency and likelihood of generating new small molecule drug leads through the use of our large-scale computational drug design methods.